Trade Veracyte Inc - VCYT CFD

Add to favourite

19.39

1.15%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.10

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Veracyte Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	19.17
Open*	19.18
1-Year Change*	-15.77%
Day's Range*	18.99 - 19.44
52 wk Range	19.52-30.52
Average Volume (10 days)	585.71K
Average Volume (3 months)	13.13M
Market Cap	1.87B
P/E Ratio	-100.00K
Shares Outstanding	73.04M
Revenue	343.15M
EPS	-0.69
Dividend (Yield %)	N/A
Beta	1.68
Next Earnings Date	Feb 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	19.17	0.58	3.12%	18.59	19.31	18.49
Apr 17, 2024	18.81	-0.17	-0.90%	18.98	19.29	18.70
Apr 16, 2024	18.89	-0.14	-0.74%	19.03	19.13	18.68
Apr 15, 2024	19.33	-0.76	-3.78%	20.09	20.15	19.09
Apr 12, 2024	20.20	-0.28	-1.37%	20.48	20.54	19.99
Apr 11, 2024	20.70	0.04	0.19%	20.66	20.81	20.33
Apr 10, 2024	20.66	0.94	4.77%	19.72	20.97	19.65
Apr 9, 2024	21.40	0.81	3.93%	20.59	21.41	20.59
Apr 8, 2024	20.64	0.50	2.48%	20.14	20.66	20.02
Apr 5, 2024	20.06	0.29	1.47%	19.77	20.31	19.65
Apr 4, 2024	20.12	-0.50	-2.42%	20.62	21.06	20.11
Apr 3, 2024	20.59	0.40	1.98%	20.19	20.94	19.98
Apr 2, 2024	20.46	-0.52	-2.48%	20.98	20.98	20.42
Apr 1, 2024	21.61	-0.34	-1.55%	21.95	21.95	21.39
Mar 28, 2024	22.09	0.62	2.89%	21.47	22.32	21.47
Mar 27, 2024	21.69	0.46	2.17%	21.23	21.70	21.15
Mar 26, 2024	21.11	0.01	0.05%	21.10	21.41	20.57
Mar 25, 2024	20.97	0.12	0.58%	20.85	21.56	20.82
Mar 22, 2024	21.05	-0.31	-1.45%	21.36	21.38	20.87
Mar 21, 2024	21.52	-0.20	-0.92%	21.72	22.20	21.49

Veracyte Inc Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Veracyte Inc Earnings Release Q1 2024 Veracyte Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 17:00	Country US	Event Veracyte Inc Annual Shareholders Meeting Veracyte Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Veracyte Inc Earnings Release Q2 2024 Veracyte Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	296.536	219.514	117.483	120.368	92.008
Revenue	296.536	219.514	117.483	120.368	92.008
Cost of Revenue, Total	101.582	74.4	41.455	36.523	33.078
Gross Profit	194.954	145.114	76.028	83.845	58.93
Total Operating Expense	337.617	301.417	152.872	135.495	114.241
Selling/General/Admin. Expenses, Total	168.533	134.843	87.585	81.312	63.623
Research & Development	40.079	29.531	16.962	14.564	14.42
Depreciation / Amortization	24.123	18.143	6.87	3.096	3.12
Operating Income	-41.081	-81.903	-35.389	-15.127	-22.233
Interest Income (Expense), Net Non-Operating	1.971	-1.187	-0.229	-0.677	-1.963
Other, Net	2.683	1.441	0.709	3.205	1.197
Net Income Before Taxes	-36.427	-81.649	-34.909	-12.599	-22.999
Net Income After Taxes	-36.56	-75.563	-34.909	-12.599	-22.999
Net Income Before Extra. Items	-36.56	-75.563	-34.909	-12.599	-22.999
Net Income	-36.56	-75.563	-34.909	-12.599	-22.999
Income Available to Common Excl. Extra. Items	-36.56	-75.563	-34.909	-12.599	-22.999
Income Available to Common Incl. Extra. Items	-36.56	-75.563	-34.909	-12.599	-22.999
Diluted Net Income	-36.56	-75.563	-34.909	-12.599	-22.999
Diluted Weighted Average Shares	71.5492	67.8903	53.2392	46.1382	37.0202
Diluted EPS Excluding Extraordinary Items	-0.51098	-1.11302	-0.6557	-0.27307	-0.62125
Diluted Normalized EPS	-0.481	-0.90142	-0.6557	-0.27307	-0.62125
Total Extraordinary Items
Dividends per Share - Common Stock Primary Issue
Unusual Expense (Income)	3.3	22.1
Other Operating Expenses, Total		22.4

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	90.322	82.422	80.297	75.592	72.864
Revenue	90.322	82.422	80.297	75.592	72.864
Cost of Revenue, Total	29.688	26.229	26.831	26.008	25.03
Gross Profit	60.634	56.193	53.466	49.584	47.834
Total Operating Expense	98.373	92.92	85.717	85.272	83.597
Selling/General/Admin. Expenses, Total	50.051	46.481	41.688	42.731	39.964
Research & Development	12.268	12.606	11.123	10.647	9.256
Depreciation / Amortization	6.366	6.204	6.075	5.886	6.047
Unusual Expense (Income)		1.4	0		3.3
Other Operating Expenses, Total
Operating Income	-8.051	-10.498	-5.42	-9.68	-10.733
Interest Income (Expense), Net Non-Operating	1.173	1.411	2.013	-0.085	-0.223
Other, Net	-1.399	0.996	-0.034	0.89	1.309
Net Income Before Taxes	-8.277	-8.091	-3.441	-8.875	-9.647
Net Income After Taxes	-8.402	-8.091	-3.844	-8.723	-9.532
Net Income Before Extra. Items	-8.402	-8.091	-3.844	-8.723	-9.532
Net Income	-8.402	-8.091	-3.844	-8.723	-9.532
Income Available to Common Excl. Extra. Items	-8.402	-8.091	-3.844	-8.723	-9.532
Income Available to Common Incl. Extra. Items	-8.402	-8.091	-3.844	-8.723	-9.532
Diluted Net Income	-8.402	-8.091	-3.844	-8.723	-9.532
Diluted Weighted Average Shares	72.4787	72.1755	71.8288	71.6567	71.477
Diluted EPS Excluding Extraordinary Items	-0.11592	-0.1121	-0.05352	-0.12173	-0.13336
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.11592	-0.0927	-0.05352	-0.12173	-0.10335

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	248.636	243.102	375.679	187.687	96.952
Cash and Short Term Investments	178.852	173.197	349.364	159.317	77.995
Cash & Equivalents	154.247	173.197	349.364	159.317	77.995
Total Receivables, Net	44.021	41.461	18.461	19.329	13.168
Accounts Receivable - Trade, Net	44.021	41.461	18.461	19.329	13.168
Total Inventory	14.294	11.225	4.657	6.806	3.402
Prepaid Expenses	11.469	17.219	3.197	2.235	2.387
Other Current Assets, Total
Total Assets	1156.42	1187.82	457.163	275.212	120.638
Property/Plant/Equipment, Total - Net	30.862	31.141	16.833	17.741	8.94
Property/Plant/Equipment, Total - Gross	56.844	52.622	33.23	31.821	20.946
Accumulated Depreciation, Total	-25.982	-21.481	-16.397	-14.08	-12.006
Goodwill, Net	695.891	707.904	2.725	2.725	1.057
Intangibles, Net	174.866	202.731	59.924	65.019	12
Other Long Term Assets, Total	6.167	2.947	2.002	2.04	1.689
Total Current Liabilities	62.614	64.151	16.781	17.469	13.059
Accounts Payable	11.911	12.36	3.116	2.328	2.516
Accrued Expenses	41.844	43.105	13.294	15.141	9.186
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	8.859	7.559	0.371
Total Liabilities	81.222	91.311	35.931	35.757	40.883
Total Long Term Debt	0.4	0.6	0.81	0.694	23.925
Long Term Debt		0	0.81	0.694	23.925
Capital Lease Obligations	0.4	0.6			0
Other Liabilities, Total	13.677	20.968	18.34	17.594	3.899
Total Equity	1075.2	1096.51	421.232	239.455	79.755
Preferred Stock - Non Redeemable, Net	0		0	0	0
Common Stock	0.072	0.071	0.058	0.05	0.041
Additional Paid-In Capital	1500.19	1468.68	702.768	486.09	313.8
Retained Earnings (Accumulated Deficit)	-393.717	-357.157	-281.594	-246.685	-234.086
Total Liabilities & Shareholders’ Equity	1156.42	1187.82	457.163	275.212	120.638
Total Common Shares Outstanding	71.9594	71.1231	58.2005	49.6253	40.8632
Current Port. of LT Debt/Capital Leases	0	1.127		0	1.357
Deferred Income Tax	4.531	5.592
Other Equity, Total	-31.346	-15.083
Short Term Investments	24.605

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	271.163	259.48	251.503	248.636	238.516
Cash and Short Term Investments	202.463	191.142	177.89	178.852	170.112
Cash & Equivalents	202.463	191.142	177.89	154.247	170.112
Total Receivables, Net	39.297	42.365	45.489	44.021	40.068
Accounts Receivable - Trade, Net	39.297	42.365	45.489	44.021	40.068
Total Inventory	15.887	11.572	13.306	14.294	13.798
Prepaid Expenses	13.516	14.401	14.818	11.469	14.538
Total Assets	1124.94	1161.11	1157.12	1156.42	1125.96
Property/Plant/Equipment, Total - Net	30.585	30.965	29.38	30.862	31.122
Goodwill, Net	693.176	698.92	699.718	695.891	676.885
Intangibles, Net	123.567	164.744	170.226	174.866	176.542
Other Long Term Assets, Total	6.452	7.005	6.292	6.167	2.892
Total Current Liabilities	57.26	58.151	55.993	62.614	58.352
Accounts Payable	12.531	12.895	15.655	11.911	11.114
Accrued Expenses	39.835	39.4	34.717	41.844	36.095
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	4.894	5.856	5.621	8.859	9.956
Total Liabilities	70.884	78.396	75.86	81.222	77.78
Total Long Term Debt	0.1	0.2	0.2	0.4	0.5
Long Term Debt
Deferred Income Tax	3.644	4.707	4.594	4.531	4.342
Other Liabilities, Total	9.88	15.338	15.073	13.677	14.586
Total Equity	1054.06	1082.72	1081.26	1075.2	1048.18
Common Stock	0.073	0.073	0.072	0.072	0.072
Additional Paid-In Capital	1528.01	1520.64	1509.86	1500.19	1492.04
Retained Earnings (Accumulated Deficit)	-439.828	-410.21	-401.808	-393.717	-389.873
Total Liabilities & Shareholders’ Equity	1124.94	1161.11	1157.12	1156.42	1125.96
Total Common Shares Outstanding	72.9937	72.6432	72.3831	71.9594	71.7415
Capital Lease Obligations	0.1	0.2	0.2	0.4	0.5
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Other Equity, Total	-34.197	-27.783	-26.866	-31.346	-54.066
Current Port. of LT Debt/Capital Leases				0	1.187
Short Term Investments	0	0	0	24.605	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-36.56	-75.563	-34.909	-12.599	-22.999
Cash From Operating Activities	7.535	-31.621	-9.711	-3.232	-13.521
Cash From Operating Activities	25.928	19.593	7.944	4.117	3.92
Non-Cash Items	34.415	26.388	17.735	10.096	6.209
Cash Taxes Paid	0.57	0.112	0.112	0.035	0.079
Cash Interest Paid	0.009	0.009	0.013	0.332	1.547
Changes in Working Capital	-16.381	4.219	-0.481	-4.846	-0.651
Cash From Investing Activities	-29.387	-739.206	-3.837	-42.733	-1.874
Capital Expenditures	-8.549	-5.376	-2.837	-2.756	-1.874
Other Investing Cash Flow Items, Total	-20.838	-733.83	-1	-39.977	0
Cash From Financing Activities	3.494	596.32	203.595	127.287	59.499
Financing Cash Flow Items	-3.167	-9.029	-3.845	0	0.403
Issuance (Retirement) of Stock, Net	7.942	605.349	207.54	152.495	59.388
Issuance (Retirement) of Debt, Net	-1.281	0	-0.1	-25.208	-0.292
Net Change in Cash	-18.95	-176.021	190.047	81.322	44.104
Deferred Taxes	0.133	-6.258
Foreign Exchange Effects	-0.592	-1.514

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-8.091	-36.56	-32.716	-23.993	-14.461
Cash From Operating Activities	-2.172	7.535	-2.209	-9.235	-8.872
Cash From Operating Activities	6.67	25.928	19.372	13.048	6.556
Deferred Taxes	0	0.133	-0.27	-0.118	-0.003
Non-Cash Items	9.71	34.415	27.388	18.315	7.447
Cash Interest Paid		0.009	0	0	0
Changes in Working Capital	-10.461	-16.381	-15.983	-16.487	-8.411
Cash From Investing Activities	24.08	-29.387	-2.953	-11.76	-2.453
Capital Expenditures	-0.993	-8.549	-6.677	-4.963	-2.453
Other Investing Cash Flow Items, Total	25.073	-20.838	3.724	-6.797	0
Cash From Financing Activities	1.685	3.494	3.401	1.915	1.99
Financing Cash Flow Items	-2.277	-3.167	-2.639	-1.865	-1.447
Issuance (Retirement) of Stock, Net	3.962	7.942	6.134	3.877	3.537
Issuance (Retirement) of Debt, Net	0	-1.281	-0.094	-0.097	-0.1
Net Change in Cash	23.643	-18.95	-3.085	-19.75	-9.582
Foreign Exchange Effects	0.05	-0.592	-1.324	-0.67	-0.247
Cash Taxes Paid		0.57	-0.43	0.064

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Veracyte Inc Company profile

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).

Equity composition

Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%

Industry:

Bio Diagnostics & Testing

6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024